drugset
drugset / Trial / NCT05137418

Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years

NCT05137418 ↗

Phase 3 Completed 1000 enrolled Sinovac Research and Development Co., Ltd.
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This is an open-labelled, bridging phase Ⅲ clinical trial of COVID-19 Vaccine manufactured by Sinovac Research \& Development Co., Ltd. The main purpose of this study is to evaluate the superiority of the COVID-19 Vaccine in healthy population aged from 3 to 11 years against that in adults aged 18-26 years.

Timeline

Start
2021-11-27
Primary completion
2023-01-27
Completion
2023-01-27

Drugs

EvaluationDrugModalityDoseRoute
Subject CoronaVac Vaccine 600 unknown —

Indications

COVID-19